KWM advising HK-listed RemeGen’s planned $626mln secondary listing in STAR Market

King & Wood Mallesons is advising RemeGen, a Hong-Kong listed biomedicine maker, on its planned $626 million secondary listing in STAR Market.

Established in 2008, the Yantai-headquartered RemeGen focuses on making therapeutic antibody medicines such as ADC and antibody fusion protein. In November 2020, the company completed its $590 million IPO in Hong Kong, which created the highest global biotech IPO fundraising record in 2020.

According to the company’s prospectus, the KWM team is led by partners Gao Yimin, Sun Ji, and Li Qiang.

Huatai United Securities serves as the sponsor.


To contact the editorial team, please email